Adjunct Associate Professor, Department of Surgery, Robert Wood Johnson Medical School, New Brunswick, NJ.
Wounds. 2020 Feb;32(2):66-68.
Radiation therapy (RT) following breast-conserving surgical excision of cancer reduces cancer-related mortality and recurrence.1 However, most patients experience acute radiation dermatitis (ARD) within weeks after beginning RT2; symptoms of ARD, including severe skin erythema, dryness, moist or dry desquamation, and/or ulceration, may interrupt radiotherapy. This can negatively affect patient quality of life (QoL) and cancer outcomes. Acute radiation dermatitis is not to be confused with chronic radiation dermatitis, which can lead to fibrosis, skin atrophy, pigmentation, and telangiectasia months to years after RT.3 Evidence-based guidelines4 to both prevent and treat ARD recommend the application of 1 of 2 topical interventions during and/or after RT: (1) corticosteroids to improve ARD-related discomfort and itching5 or (2) 1% silver sulfadiazine (SSD) cream to reduce ARD-related dermatitis scores.6 This Evidence Corner reviews evidence supporting the 2 aforementioned topical interventions for patients undergoing RT for breast cancer.
放射治疗（RT）继乳腺癌切除术切除癌症后，可降低癌症相关死亡率和复发率。1 然而，大多数患者在开始 RT2 后数周内会出现急性放射性皮炎（ARD）；ARD 的症状包括严重的皮肤红斑、干燥、湿性或干性脱屑和/或溃疡，可能会中断放射治疗。这会对患者的生活质量（QoL）和癌症结果产生负面影响。急性放射性皮炎不应与慢性放射性皮炎混淆，后者可导致 RT 后数月至数年出现纤维化、皮肤萎缩、色素沉着和毛细血管扩张。3 有循证指南4 建议在 RT 期间和/或之后使用 2 种局部干预措施之一来预防和治疗 ARD：（1）皮质类固醇可改善 ARD 相关的不适和瘙痒5 或（2）1%磺胺嘧啶银（SSD）乳膏可降低 ARD 相关的皮炎评分。6 本证据角为正在接受乳腺癌 RT 治疗的患者审查了支持上述 2 种局部干预措施的证据。
